Header Logo
Keywords
Last Name
Institution
Announcement

You can now add alternative names! Click here to add other names that you've published under.

Hong-Yu Li

TitleProfessor
InstitutionUniversity of Arkansas for Medical Sciences
DepartmentCollege of Pharmacy, College of Provost
DivisionPharmaceutical Science
Address200 South Cedar
Mail Slot # 622
Little Rock AR 72202
Phone501-296-1154
vCardDownload vCard

    Collapse Research Funds 
    Collapse principal investigator/co-principal investigator research activities
    R01CA197178     (LI, HONG-YU)Sep 1, 2016 - Aug 31, 2020
    NIH/Nat. Cancer Institute
    Selective RET Kinase and Its Mutant Inhibitors for the Treatment of Medullary Thyroid Cancer
    Role: Principal Investigator

    R01CA194094     (LI, HONG-YU)Sep 1, 2016 - Jul 31, 2019
    NIH/Nat. Cancer Institute
    Discovery and Development of a Selective pan-FLT3-ITD Kinase Inhibitor Clinical Candidate for the Treatment of FLT3-ITD-Driven AML
    Role: Principal Investigator

    340316     (LI, HONG-YU)Apr 1, 2016 - Jun 30, 2016
    NIH/Nat. Cancer Institute - Pass Through: University of Arizona
    Discovery and Development of a Selective pan-FLT3-ITD Kinase Inhibitor Clinical Candidate for the Treatment of FLT3-ITD-Driven AML
    Role: Principal Investigator

    R01CA197178     (LI, HONG-YU)Sep 30, 2015 - Aug 31, 2020
    NIH/NCI
    Selective RET Kinase and Its Mutant Inhibitors for the Treatment of Medullary Thyroid Cancer
    Role: Principal Investigator

    R41CA195826     (LI, HONG YU)Sep 1, 2015 - Aug 31, 2016
    NIH/NCI
    Pre-IND Study of Pz-1, a dual pan-RET/VEGFR2 inhibitor for the Treatment of RET-driven Disease
    Role: Principal Investigator

    R01CA194094     (LI, HONG-YU)Aug 1, 2015 - Jul 31, 2019
    NIH/NCI
    Discovery and Development of a Selective pan-FLT3-ITD Kinase Inhibitor Clinical Candidate for the Treatment of FLT3-ITD-Driven AML
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions. Don't see publications published under other names? Login to add alternative names.
    List All   |   Timeline
    1. Gunaganti N, Kharbanda A, Lakkaniga NR, Zhang L, Cooper R, Li HY, Frett B. Catalyst free, C-3 functionalization of imidazo[1,2-a]pyridines to rapidly access new chemical space for drug discovery efforts. Chem Commun (Camb). 2018 Nov 15; 54(92):12954-12957. PMID: 30375586.
      View in: PubMed
    2. Honda-Ozaki F, Terashima M, Niwa A, Saiki N, Kawasaki Y, Ito H, Hotta A, Nagahashi A, Igura K, Asaka I, Li HL, Yanagimachi M, Furukawa F, Kanazawa N, Nakahata T, Saito MK. Pluripotent Stem Cell Model of Nakajo-Nishimura Syndrome Untangles Proinflammatory Pathways Mediated by Oxidative Stress. Stem Cell Reports. 2018 06 05; 10(6):1835-1850. PMID: 29731430.
      View in: PubMed
    3. Agrawal PB, Wang R, Li HL, Schmitz-Abe K, Simone-Roach C, Chen J, Shi J, Louie T, Sheng S, Towne MC, Brainson CF, Matthay MA, Kim CF, Bamshad M, Emond MJ, Gerard NP, Kleyman TR, Gerard C. The Epithelial Sodium Channel Is a Modifier of the Long-Term Nonprogressive Phenotype Associated with F508del CFTR Mutations. Am J Respir Cell Mol Biol. 2017 12; 57(6):711-720. PMID: 28708422.
      View in: PubMed
    4. Choi IY, Lim H, Estrellas K, Mula J, Cohen TV, Zhang Y, Donnelly CJ, Richard JP, Kim YJ, Kim H, Kazuki Y, Oshimura M, Li HL, Hotta A, Rothstein J, Maragakis N, Wagner KR, Lee G. Concordant but Varied Phenotypes among Duchenne Muscular Dystrophy Patient-Specific Myoblasts Derived using a Human iPSC-Based Model. Cell Rep. 2016 06 07; 15(10):2301-2312. PMID: 27239027.
      View in: PubMed
    5. Li HL, Gee P, Ishida K, Hotta A. Efficient genomic correction methods in human iPS cells using CRISPR-Cas9 system. Methods. 2016 05 15; 101:27-35. PMID: 26525194.
      View in: PubMed
    6. Li HL, Fujimoto N, Sasakawa N, Shirai S, Ohkame T, Sakuma T, Tanaka M, Amano N, Watanabe A, Sakurai H, Yamamoto T, Yamanaka S, Hotta A. Precise correction of the dystrophin gene in duchenne muscular dystrophy patient induced pluripotent stem cells by TALEN and CRISPR-Cas9. Stem Cell Reports. 2015 Jan 13; 4(1):143-154. PMID: 25434822.
      View in: PubMed
    7. Li HL, Nakano T, Hotta A. Genetic correction using engineered nucleases for gene therapy applications. Dev Growth Differ. 2014 Jan; 56(1):63-77. PMID: 24329887.
      View in: PubMed
    Li's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description
    Physical Neighbors Expand Description
    _